Clinical trials: Vancomycin
Cross Infection, Carbapenem Resistant Bacterial Infection
Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units
Investigate the epidemiology, risk factors and impact on clinical practice of healthcare-associated infections with emergent highly drug-resistant (eHDR) pathogens, particularly carbapenem resistant enterobacteriaceae and…
- Conditions
- Cross Infection, Carbapenem Resistant Bacterial Infection, Vancomycin-Resistant Enterococcal Infection, Critical Illness
- Trial name
- NOSOREA3 (NCT06392568)
- Testing
- epidemiological records
- Where
- Tunisia
- Volunteers
- 500 people
- Sponsor
- Abderrahmane Mami Hospital
Clostridium Difficile
A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System
The primary objective is to compare fidaxomicin versus vancomycin for the sustained clinical cure of Clostridium difficile Infection (CDI) in adult patients receiving immunosuppressive therapy.
- Trial name
- FREEDOM (NCT01775397)
- Testing
- Fidaxomicin, Vancomycin
- Where
- 16 sites in Austria, Denmark and 5 more
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Europe Ltd.
Vancomycin Therapy
Dose Enhancement of Vancomycin IN Everyday Patients
Current Australian guidelines for vancomycin commonly underdoses individuals particularly in the first 48 hours. The aim of the trial is to compare two dosing regimens; the current Australian guidelines versus a more…
- Trial name
- DEVINE (NCT01427842)
- Testing
- DEVINE vancomycin regimen
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- The Canberra Hospital
Gram-Positive Bacterial Infections, Staphylococcus Infections
Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
To evaluate the safety and efficacy of tigecycline in the treatment of selected serious infections caused by VRE. The primary efficacy endpoint will be the clinical response for all subjects.
- Conditions
- Gram-Positive Bacterial Infections, Staphylococcus Infections, Vancomycin Resistance, Methicillin Resistance
- Trial name
- NCT00079976
- Testing
- Tigecycline
- Volunteers
- 174 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Surgical Site Infection
Dose Escalation Trial of Intrasite Vancomycin Pharmacokinetics
Surgical wound infections remain a serious problem despite aseptic techniques and the use of prophylactic systemic antibiotics. Such infections can occur at rates up to ~20% in high-risk patients receiving long segment…
- Trial name
- NCT01764750
- Testing
- Intrasite Vancomycin, IV Vancomycin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Infection, Surgery
Topical Vancomycin for Neurosurgery Wound Prophylaxis
This study is a collaboration between New York Presbyterian (NYP)-Columbia and NYP-Cornell that seeks to evaluate the use of topical vancomycin and its reduction on surgical site infection (SSI) in neurosurgical procedures.
- Conditions
- Infection, Surgery, Nervous System Diseases
- Trial name
- Vanguard (NCT02284126)
- Testing
- Vancomycin
- Where
- United States
- Volunteers
- 1,103 people
- Sponsor
- Columbia University
Cellulitis
The Effects of Daptomycin and Cytokines Production in Comparison With Vancomycin
Primary: To determine the influence of daptomycin on inflammatory cytokine (IL-1, TNF and IL-6) for the treatment of complicated cellulitis/erysipela compared with alternative treatment (vancomycin or oxacillin).
- Trial name
- NCT01626560
- Testing
- Daptomycin, Vancomycin
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital Universitario Evangelico de Curitiba
Sepsis, Sepsis Mrsa
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
The goal of this quasi-experimental interventional study is to determine the effectiveness of a multifaceted stewardship intervention in reducing overall vancomycin use in five tertiary care Pediatric Intensive Care Units (PICU).
- Conditions
- Sepsis, Sepsis Mrsa, Sepsis Bacteremia, Antimicrobial - Induced Nephropathy
- Trial name
- REVAMP (NCT05975671)
- Testing
- Multifaceted de-implementation strategy to reduce vancomycin overuse
- Where
- 4 sites in United States
- Volunteers
- 52,500 people
- Sponsor
- Children's Hospital of Philadelphia
Primary Sclerosing Cholangitis, Post- Orthotopic Liver Transplantation
Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients
The purpose of the study is to investigate the safety and efficacy of oral vancomycin in patients with recurrent Primary Sclerosing Cholangitis (PSC) after liver transplantation.
- Trial name
- NCT03046901
- Testing
- Vancomycin
- Where
- United States
- Sponsor
- Ochsner Health System
Staphylococcus Aureus, Bacteremia
Comparison of Nephrotoxicity and Hospital Costs in Patients With Methicillin-Resistant Staphylococcus Aureus Bacteremia Who Received Vancomycin Versus Teicoplanin Therapy
Staphylococcus aureus, the most virulent of the many staphylococcal species, has been recognized as one of the most important and lethal human bacterial pathogens.
- Trial name
- NCT01352936
- Where
- Taiwan
- Volunteers
- 190 people
- Sponsor
- Taipei Medical University WanFang Hospital
Blood Stream Infections, Endocarditis
Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin
1. Drug resistance of G+ cocci is a severe healthcare problem. According to the Ministry of Health National Antimicrobial Resistant Investigation Net (mohnarin) surveillance report, the isolation rate of MRSA is some 60% in…
- Conditions
- Blood Stream Infections, Endocarditis, MRSA
- Trial name
- NCT02443064
- Testing
- Vancomycin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang University
Clostridium Infections, Diarrhea
PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
This is a comparative study to investigate the safety and efficacy of PAR-101/OPT-80 (fidaxomicin) versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).
- Trial name
- NCT00468728
- Testing
- PAR-101/OPT-80, Vancomycin
- Where
- 116 sites in United States, Belgium and 7 more
- Volunteers
- 535 people
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Skin and Soft Tissue Infections
Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections
Our hypothesis is that large-dose, extended-interval vancomycin (30 mg/kg IV q24h) administration provides non-inferior clinical efficacy and microbiological efficacy to standard vancomycin (15 mg/kg IV q12h) administration for…
- Trial name
- VOD (NCT01037192)
- Testing
- vancomycin
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- Fraser Health
Osteoarthritis, Knee, Osteoarthritis, Hip
Role of Topical Vancomycin in Reducing Infections in Hip and Knee Arthroplasty
The study is designed to assess the efficacy of vancomycin powder and dilute povidone-iodine lavage (VIP protocol) in reducing the PJI after primary Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA).
- Conditions
- Osteoarthritis, Knee, Osteoarthritis, Hip, Rheumatoid Arthritis, Avascular Necrosis of Hip
- Trial name
- NCT05972603
- Testing
- 1.0 g Vancomycin powder into the wound, 0,35% povidone-iodine solution lavage
- Where
- Poland
- Volunteers
- 1,000 people
- Sponsor
- Independent Public Healthcare Center in Rypin
Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.
- Trial name
- PSC (NCT01802073)
- Testing
- Oral Vancomycin
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Stanford University
Bacterial Infections, Infection
Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
This is a Phase II, multi-center, randomized, double-blind study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in patients with acute bacterial skin and skin structure infection.
- Trial name
- NCT01119105
- Testing
- BC-3781, Vancomycin
- Where
- 9 sites in United States
- Volunteers
- 210 people
- Sponsor
- Nabriva Therapeutics AG
Sepsis, Infection
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
Babies aged 0 to 90 days with a suspected infection requiring treatment with vancomycin will be recruited. They will be randomised to receive vancomycin as an intermittent infusion (over 1 hour) or as a continuous infusion (over…
- Conditions
- Sepsis, Infection, Bacteremia
- Trial name
- NCT02210169
- Testing
- Continuous infusion of vancomycin
- Where
- 2 sites in Australia
- Volunteers
- 111 people
- Sponsor
- Murdoch Childrens Research Institute
Methicillin-Resistant Staphylococcus Aureus (MRSA), Hospital-Acquired Pneumonia
Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin
The objective of this study is to review the local management of patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia treated with vancomycin or linezolid with the goal to define if any difference…
- Trial name
- NCT01561469
- Testing
- Linezolid, Vancomycin
- Volunteers
- 188 people
- Sponsor
- Pfizer
Clostridium Enterocolitis, Diarrhea
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea
Approximately 520 patients will be entered into this study taking place throughout Australia and Europe. This study aims to determine if an investigational drug is safe and effective for treating symptoms of C.
- Trial name
- NCT00196794
- Testing
- Tolevamer potassium-sodium (GT267-004)
- Where
- 138 sites in Australia, Austria and 12 more
- Volunteers
- 520 people
- Sponsor
- Genzyme, a Sanofi Company
Arbitrary Restriction Polymorphism 1
Unexpected Pharmacokinetics of Vancomycin in Patients With Severe Acute Pancreatitis Compared With Pneumonia
The purpose of this study was to evaluate the influence of severe acute pancreatitis on the serum level of vancomycin, a glycopeptide antibacterial agent.
- Trial name
- NCT02134665
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital